Loading company
ONCBeone Medicines Ltd.$48BA+Just reported
From Arbutus Biopharma's results release of November 10, 2026; its quarterly report has since been filed.
Actual
$299K
-43% y/y
-71% q/q
Guided
—
No guide given
Actual
$0.30
Guided
—
No guide given
Actual
-$10.5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Built from Arbutus Biopharma Corp.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Arbutus Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$3.89+1.6%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Grade D+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Arbutus Biopharma Corp.’s grade history. The other 39 go back to November 2016.
